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Abstract 
Background: Psychotic symptoms fluctuate over time and effective and regular monitoring 
may contribute to relapse prevention and improve long-term outcomes. In this proof-of-
concept study we test the feasibility, acceptability and potential usefulness of a novel digital 
method assessing the association between physiological signals and psychotic symptom 
distress.  
Method: Fifteen participants with first episode psychosis were asked to use a self-assessment 
mobile phone application for psychotic symptom monitoring for ten days while using a wrist 
worn device continuously recording heart rate variability (HRV) and electrodermal activity 
(EDA). We compared physiological activity when participants reported experiencing 
distressing and non-distressing psychotic symptoms. 
Results: Participants completed on average 76% of the mobile phone symptom assessments. 
When reporting distressing hallucinations and delusions participants had significantly higher 
EDA levels and non-significant lower HRV values compared to when these symptoms were 
non-distressing.   
Discussion: This study provides further evidence linking psychotic symptom’s distress, as 
experienced in everyday life, and autonomic deregulation. This proof-of-concept study may 
lead to further longer-term efforts to identify relapse biosignatures using automated methods 
based on passive monitoring. This method may allow for earlier interventions, contribute to 
improve relapse prevention and reduce symptoms interfering with recovery.  
 
Keywords: Schizophrenia; Psychosis; Wearable; Autonomic; eHealth; mHealth.  
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Introduction 
Relapse after the first episode of psychosis is common (Robinson et al., 1999) and it is 
associated with poorer recovery, increased distress, depression and suicidal thoughts 
(Birchwood & Spencer, 2001; Birchwood, Todd, & Jackson, 1998). Relapse prevention is 
therefore a highly desired outcome. Early warning signs of relapse usually comprise dysphoria 
and the emergence of attenuated but distressing psychotic symptoms (e.g. hearing voices), 
appearing over a period of typically five days (Brown, Kim, Mitchell, & Inskip, 2010; Cella, 
Cooper, Dymond, & Reed, 2008; Gleeson, Rawlings, Jackson, & McGorry, 2005). Evidence 
using ambulatory methods for tracking symptoms suggests that high levels of symptom 
related distress and poor coping abilities are amongst the most important factors contributing 
to  relapse  (Lardinois et al., 2007). 
There is consensus that regular symptom monitoring may improve early intervention and 
relapse prevention, but it is not clear how often this should occur (Spaniel et al., 2008). 
Regular monitoring conducted by clinicians is also resource intensive and may be difficult to 
implement for early intervention services. It has been suggested that mobile health (mHealth) 
technologies could help to achieve frequent monitoring in the context of limited resources 
(Kumar et al., 2013; Narayan & Manji, 2016). However, mHealth current monitoring tools for 
psychosis require symptom self-assessment which may be deliberately avoided when 
experiencing more severe or distressing symptoms. Passive remote monitoring (pRMT) might 
provide a solution if it is associated with information on symptoms fluctuation and it is well 
tolerated. 
There is evidence that people with psychosis have autonomic abnormalities and these are 
associated with psychotic symptoms and lower functioning (Bar et al., 2005; Clamor, Lincoln, 
Thayer, & Koenig, 2016; Fujibayashi et al., 2009). Studies suggest that people with psychosis 
have reduced vagal tone and heart rate variability (HRV) (Bar et al., 2005; Moon, Lee, Kim, & 
Hwang, 2013) and this is associated with illness chronicity (Toichi et al., 1999), low scores on 
the Global Assessment of Functioning (Khandoker, M. Fujibayashi, Moritani, & Palaniswami, 
2010), and symptoms severity (Kim et al., 2004). Studies investigating sympathetic regulation 
found that people with psychosis have elevated levels of electrodermal activity, (EDA) (Zahn 
et al., 1997) and these are thought to be dependent from a limited parasympathetic capacity 
to down-regulate sympathetic activity (Montaquila, Trachik, & Bedwell, 2015).  
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Until recently most studies assessed the association between symptoms and physiological 
abnormalities under laboratory conditions. Developments in mHealth devices have now 
made it possible to measure autonomic parameters using non-invasive wearable devices and 
there is evidence of their acceptability in people with psychosis (e.g. Cella et al., 2018). Given 
the association between autonomic deregulation and psychotic symptoms, pRMT might help 
to identify increases in symptom related distress which may be of use in averting extreme 
symptom worsening and relapse. 
This proof-of-concept study combines active and passive monitoring methods to explore the 
association between psychotic symptoms distress fluctuations and changes in autonomic 
parameters in a group of individuals with first episode psychosis. According to Montaquila et 
al.,  (Montaquila et al., 2015) we hypothesise that high levels of distress associated with 
hallucinations and delusions will be associated with low Heart Rate Variability (HRV) and high 
Electrodermal Activity (EDA). 
 
Method 
Participants 
We recruited individuals under the care of early intervention teams in the South London and 
Maudsley NHS Foundation Trust. The inclusion criteria were: i) having experienced a psychotic 
episode, ii) aged between 18 and 35 years; iii) onset of psychosis within the last 12 months; 
iv) able to provide written informed consent.  
Measures 
Participants completed an assessment of symptoms using the Positive and Negative 
Syndrome Scale (PANSS) (Kay, Fiszbein, & Opler, 1987) and functioning using the Global 
Assessment of Functioning (GAF) (Hall, 1995). Clinical and medication information was 
extracted from participants’ electronic health records. Mean chlorpromazine equivalent 
levels for antipsychotic medications were calculated according to Woods (Woods, 2003). 
Then participants were instructed on how to use a wrist worn device, the Empatica E4 
(https://www.empatica.com/en-gb/research/e4/). This device has sensors recording 
physiological and behavioural measures including heart rate, motion, electrodermal activity 
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and skin temperature. Participants were asked to wear the device during day time (i.e. from 
when they wake up in the morning until they went to bed in the evening). Alongside the wrist 
device, participants were asked to use a mobile phone app(lication) for symptom self-
assessment, called ClinTouch, developed for people with psychosis (Palmier-Claus et al., 
2012a; Palmier-Claus et al., 2013). This app prompts participants at four pseudo-random 
times per day (between 11am to 9pm) to answer symptoms rating questions (e.g. “Have you 
heard a voice telling you that you are worthless today?”; “I have felt like I could read other 
people's thoughts”). Each participant rates up to twelve symptoms validated against the 
PANSS (Palmier-Claus et al., 2012b) in addition to personally relevant early warning signs 
using scores ranging from 1 (not present) to 7 (present). These included rating of anxiety, 
hallucinations, suspiciousness, depression, somatic concern, social withdrawal, hostility, 
conceptual disorganisation but not only. The mobile phone app allows for personalisation so 
that only relevant symptom rating prompts are sent to participants. For each symptom rated 
as present the app prompts participants to rate the associated distress level ranging from 1 
to 7. A rating above three was considered indicative of a distressing symptom. All the 
participants in this study had hallucinations and delusions and each ClinTouch assessment 
asked to rate these symptoms. Participants were asked to use simultaneously ClinTouch and 
the E4 device for 10 consecutive days. Devices acceptability was evaluated using a 
questionnaire including questions on the device level of disruption to participants’ life, if the 
device was easy to use or stopped participants to do activities, and whether the experience 
of using the device was enjoyable or caused any embarrassment. This measure was used in 
previous studies involving people with psychosis and similar mHealth devices (e.g. Edwards, 
Cella, Tarrier, & Wykes, 2016).  
Analysis 
For analysis we considered samples of physiological recording collected at the time 
participants completed the mobile phone symptom self-assessment survey. We considered 
physiological recording samples of 20 minutes, from 10 minutes before the symptoms self-
assessment survey trigger to 10 minutes after. 
The electrodermal activity data was pre-processed for artefact using Ledalab 3.2.2 toolbox 
from Matlab (Benedek & Kaernbach, 2010). For each sample we used this software to extract 
EDA mean magnitude. HRV was computed from inter-beat intervals values using Kubios HRV 
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software (Tarvainen, Niskanen, Lipponen, Ranta-Aho, & Karjalainen, 2014). For HRV analysis 
we considered the standard deviation of all normal heart beat peak interval (SDNN). This 
measure is considered more accurate over shorter samples (i.e. less than 1 hour) (Okruszek, 
Dolan, Lawrence, & Cella, 2017; Sollers, Buchanan, Mowrer, Hill, & Thayer, 2007). The E4 
device also collected information on movement using a 3-axis accelerometer. From this 
information we computed an overall activity measure by means of a standard Euclidean 
metric. We used this measure as a covariate in the analysis. This is because electrodermal 
activity and HRV parameters are affected by the body metabolic state and controlling for 
activity helps to exclude physiological changes dependent on exercise and physical exertion.   
We assessed the acceptability of the procedures employed in this study by considering the 
proportion of participants endorsing a positive rating on the acceptability feedback 
questionnaire items (i.e. endorsing agree on strongly agree).  
We used multi-level logistic modelling with participant, our cluster variable, considered as a 
random-effect, while the effects of the predictors (i.e. SDNN and EDA) on the outcome 
variable (i.e. symptoms distress present or absent) were described as fixed effects. Analysis 
was conducted using the XTMELOGIT command in Stata (Version 15) (StataCorp, 2017) in line 
with similar studies (e.g. Edwards, Cella, Emsley, Tarrier, & Wykes, 2018; Kimhy, Myin-
Germeys, Palmier-Claus, & Swendsen, 2012). The effect of predictors on the outcome, 
representing the regression coefficients, are expressed as Z scores and odd ratios.  
 
 
Results 
Of the fifteen participants recruited, fourteen completed the whole study. One participant 
withdrew after a sudden family bereavement. The participants were predominantly men 
(80%) with a mean age of 28.1 (SD3.8) and were all prescribed antipsychotic medications 
(mean chlorpromazine equivalent 238.7 (SD 174.1)). The mean PANSS positive score was 17.2 
(SD 4.5), the negative was 17.9 (SD 4.78) and the general was 35.7 (SD 10.1). The GAF mean 
score was 48.8 (SD 9.3). 
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Participants completed an average of 76% of the ClinTouch assessments over the study period 
(i.e. on average three out of four assessments per day). All participants used the watch 
according to the instructions received and completed the device acceptability questionnaire. 
Results from the acceptability questionnaire showed that both devices were easy to use and 
did not have significant side effects with over 80% of the participants rating the app and the 
wearable device as easy to use and non-disruptive and the experience of using the devices as 
enjoyable. 
Overall, we were able to combine data from ClinTouch and the E4 device for 157 symptoms 
surveys (each assessing both hallucinations and delusions). Of the completed surveys we had 
47% with hallucinations rated as distressing and 45% with delusions rated as distressing. 
Participants rated a minimum of 6 and a maximum of 16 surveys with no significant 
differences in completion levels. 
The model performed on delusion (Wald X2(2)=8.75, p=0.013) showed that EDA values were 
higher when experiencing distressing (z=2.98, p=0.003; OR=1.05; 95%CI 1.02-1.08) compared 
to experiencing not-distressing delusion but there was no significant difference in SDNN 
values (z=-0.97, p=0.3; OR=0.99; 95%CI 0.98-1.02). A similar model performed on 
hallucination (Wald X2(2)=8.01, p=0.02) showed that EDA values were higher when 
experiencing distressing (z=2.88, p=0.004; OR=1.06; 95%CI 1.02-1.09) compared to non-
distressing hallucinations but there was no significant difference in SDNN (z=-0.95, p=0.34; 
OR=0.99; 95%CI 0.98-1.02) (see figure 1).  
 
--------- Figure 1 about here ---------- 
 
Discussion 
This proof-of-concept study tested the combination of active and passive monitoring methods 
for symptom monitoring with the longer-term aim to develop a method that can use 
predominantly passive information to improve symptom monitoring and contribute towards 
relapse prevention in psychosis. As we tested mHealth devices in people with first episode 
psychosis for the first time and a aim of this study was to assess acceptability and ease of use 
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of these devices. The results support a high level of uptake and acceptability of the wearable 
device used and high completion levels for the mobile phone surveys. 
Our results also suggest that when reporting distressing hallucinations and delusions 
participants had significantly higher EDA levels values compared to when these symptoms 
were not distressing. Associations between HRV and symptom distress were in the expected 
direction but did not reach a statistically significant threshold. These results replicate 
laboratory studies of physiological abnormalities (Kim et al., 2004) and emerging evidence 
associating these abnormalities with positive symptom fluctuations (Kimhy et al., 2017). 
Further studies consolidating the evidence on the biosignature of positive symptoms may 
have important implications for delivering improved and cost-effective outcomes.  
With new wearable technology allowing for effortless physiological recording in real-time this 
study suggests that it may be possible to measure a reliable biosignature of symptom 
exacerbation and potentially relapse risk. With these indicators linked to a clinical service the 
prospect of prevention and rapid response to symptom worsening may improve substantially. 
However, achieving this ambitious target will require further efforts to develop data handling 
algorithms and machine learning tools that can produce personalised and meaningful alerts 
for service users and clinicians (Iniesta, Stahl, & McGuffin, 2016). Limitations of this study are 
the small number of service users, potential selection bias at recruitment for those more 
familiar with technology use, the potential confounding role of medication and variability in 
cardio-metabolic fitness which is difficult to control for in the analysis. However, a recent 
review suggests that medication is unlikely to have a strong effect on autonomic activity 
(Alvares, Quintana, Hickie, & Guastella, 2016). 
There are other issues the field of mHealth and pRMT should consider including data handling, 
confidentiality and potential stigma associated with device use (Simblett et al., 2018). 
However, it is likely that the benefits of this technology will exceed these potential difficulties, 
especially in high-risk group such as people with first episode psychosis. 
With increasing evidence suggesting that mHealth devices are acceptable and easy to use the 
focus of research now should shift to develop accurate systems for prediction based 
predominantly on passive monitoring information. Efforts should also be made for building 
the necessary evidence for devices to be recommended and used as part of routine care.  
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Figure 1 
 
Figure 1: Show mean Heart Rate Variability (SDNN-standard deviation of consecutive NN in 
milliseconds) and Electrodermal Activity (EDA in microsimens) for samples where 
hallucination and delusion were reported as Distressing and Non-distressing. 
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